Development, testing, and implementation of a new procedure to assess the clinical added benefit of pharmaceuticals
OBJECTIVES: The reimbursement process for innovative health technologies in Hungary lacks any formalized assessment of clinical added benefit (CAB). The aim of this research is to present the development, retrospective testing, and implementation of a local assessment framework for determining the CAB of cancer treatments at the Department of Health Technology Assessment of the National Institute of Pharmacy and Nutrition in Hungary.
METHODS: The assessment framework was drafted after screening existing methods and a retrospective comparison of local reimbursement dossiers to that of German and French methods. The Magnitude of Clinical Benefit Scale of the European Society for Medical Oncology was chosen to rate the extent of CAB in oncology, as part of a conclusion complemented by the assessment of endpoint relevance and the quality of evidence. Several rounds of retrospective assessments have been conducted involving all clinical assessors, iterated with semistructured discussions to consolidate divergence between assessors. External stakeholders were consulted to provide feedback on the framework.
RESULTS: Retrospective assessments resulted in average more than 75 percent concordance between assessors on each element of the conclusion. Input from ten stakeholders was also incorporated; stakeholders were generally supportive, and they mostly commented on the concept, the elements of the framework, and its implementation.
CONCLUSIONS: The procedure is suitable for routine use in the decision-making process to describe the CAB of antineoplastic technologies in Hungary. Further extension of the framework is required to cover more disease areas for structured and comparable conclusions on CAB of innovative health technologies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
International journal of technology assessment in health care - 38(2022), 1 vom: 12. Juli, Seite e58 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dóczy, Veronika [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.07.2022 Date Revised 14.07.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1017/S0266462322000411 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343396904 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343396904 | ||
| 003 | DE-627 | ||
| 005 | 20231226020343.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1017/S0266462322000411 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1144.xml |
| 035 | |a (DE-627)NLM343396904 | ||
| 035 | |a (NLM)35819299 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dóczy, Veronika |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development, testing, and implementation of a new procedure to assess the clinical added benefit of pharmaceuticals |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.07.2022 | ||
| 500 | |a Date Revised 14.07.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: The reimbursement process for innovative health technologies in Hungary lacks any formalized assessment of clinical added benefit (CAB). The aim of this research is to present the development, retrospective testing, and implementation of a local assessment framework for determining the CAB of cancer treatments at the Department of Health Technology Assessment of the National Institute of Pharmacy and Nutrition in Hungary | ||
| 520 | |a METHODS: The assessment framework was drafted after screening existing methods and a retrospective comparison of local reimbursement dossiers to that of German and French methods. The Magnitude of Clinical Benefit Scale of the European Society for Medical Oncology was chosen to rate the extent of CAB in oncology, as part of a conclusion complemented by the assessment of endpoint relevance and the quality of evidence. Several rounds of retrospective assessments have been conducted involving all clinical assessors, iterated with semistructured discussions to consolidate divergence between assessors. External stakeholders were consulted to provide feedback on the framework | ||
| 520 | |a RESULTS: Retrospective assessments resulted in average more than 75 percent concordance between assessors on each element of the conclusion. Input from ten stakeholders was also incorporated; stakeholders were generally supportive, and they mostly commented on the concept, the elements of the framework, and its implementation | ||
| 520 | |a CONCLUSIONS: The procedure is suitable for routine use in the decision-making process to describe the CAB of antineoplastic technologies in Hungary. Further extension of the framework is required to cover more disease areas for structured and comparable conclusions on CAB of innovative health technologies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comparative effectiveness research (MeSH Unique ID: D057186) | |
| 650 | 4 | |a Decision making | |
| 650 | 4 | |a Health (MeSH Unique ID: D013673) | |
| 650 | 4 | |a Medical oncology (MeSH Unique ID: D008495) | |
| 650 | 4 | |a Outcome assessment | |
| 650 | 4 | |a Technology assessment | |
| 650 | 4 | |a health care (MeSH Unique ID: D017063) | |
| 650 | 4 | |a organizational (MeSH Unique ID: D003659) | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Wernerné Sódar, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Hölgyesi, Áron |e verfasserin |4 aut | |
| 700 | 1 | |a Merész, Gergő |e verfasserin |4 aut | |
| 700 | 1 | |a Gaál, Péter |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of technology assessment in health care |d 1985 |g 38(2022), 1 vom: 12. Juli, Seite e58 |w (DE-627)NLM013402048 |x 1471-6348 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2022 |g number:1 |g day:12 |g month:07 |g pages:e58 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1017/S0266462322000411 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2022 |e 1 |b 12 |c 07 |h e58 | ||